Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of histone deacetylase inhibitor in preparation of latent virus activator

A technology of deacetylase and histone, applied in the field of microbiology, can solve the problems of latent and continuous infection in patients with chronic hepatitis C

Inactive Publication Date: 2014-10-08
FIELD OPERATION BLOOD TRANSFUSION INST OF PLA SCI ACAD OF MILITARY
View PDF4 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] In recent years, anti-HCV combination therapy can make most of the patients obtain lasting virus clearance, but there are still patients with chronic hepatitis C who form a latent and persistent viral state

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of histone deacetylase inhibitor in preparation of latent virus activator
  • Application of histone deacetylase inhibitor in preparation of latent virus activator
  • Application of histone deacetylase inhibitor in preparation of latent virus activator

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1. Effect of chidamide on the growth of HIV latently infected cells

[0040] In this example, the MTT cell proliferation assay was used to detect the effect of the HDACi drug chidamide on the growth of virus latently infected cells A7, to confirm the cytotoxicity of chidamide and the concentration range for reactivating the latently infected virus.

[0041] 1.1 Experimental method

[0042] 1.1.1 Cell lines:

[0043] The HIV pseudovirus latent infection cell line J-Lat Tat-GFP Clone A7 (hereinafter referred to as A7) was donated by Dr. Eric Verdin, NIH AIDS Research and Standard Reagent Project Team, NIH AIDS Department, USA. A7 cells are human Jurkat T cells stably integrated with LTR-Tat-IRES-GFP via a viral vector. LTR (long terminal repeats) functions as a promoter and enhancer during viral transcription; the protein encoded by Tat gene can be combined with LTR to increase the transcription rate of viral genes; GFP (Green Fluorescent Protein) is a sign of H...

Embodiment 2

[0049] Example 2. Chidamide activates the HIV promoter of pseudovirus latent infection cell model A7

[0050] In this example, the HIV pseudovirus latently infected cell model A7 was used to prove the reactivation effect of chidamide and other HDACi on HIV virus promoters, and to explore the possibility of HDACi being used to prepare reactivation drugs for the in vivo storage of persistently infected viruses. See Example 1 for a description of A7 cells.

[0051] 2.1 Experimental method

[0052] The HIV pseudovirus latently infected cells A7 in the logarithmic growth phase were inoculated in a 12-well culture plate, and 1 × 10 6 cell. Then, different concentrations of chidamide were added to each well, the concentrations were: 0.5 μmol / L, 1.0 μmol / L, 2.0 μmol / L, 0.5 μmol / L vorinostat was used as a positive control, and no drug treatment was used. group is a negative control. 5% CO at 37°C 2 Cells were collected after cultured for 48h and 96h respectively, and the percentag...

Embodiment 3

[0056] Embodiment 3.HDACi activates the HIV promoter of pseudovirus latent infection cell model TZM-bl

[0057] In this example, TZM-bl, another HIV pseudovirus latently infected cell model, is used to further demonstrate the reactivation effect of Chidamide and other HDACi on HIV virus promoters.

[0058] 3.1 Experimental method

[0059] 3.1.1 Cell lines:

[0060] The HIV pseudovirus latent infection cell model TZM-bl cell was donated by the NIH AIDS Research and Standard Reagent Project Group of the NIH AIDS Department in the United States. It is a human Hela cell that stably integrates the HIV LTR promoter and the luciferase gene (Luc). When the HIV promoter When activated, luciferase is produced in the cells and can be analyzed with a luciferase assay kit. The culture medium of TZM-bl cells is DMEM medium supplemented with 10% FBS.

[0061] 3.1.2 Experimental scheme:

[0062] The HIV pseudovirus latently infected cells TZM-bl in the logarithmic growth phase were inoculat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a benzamide histone deacetylase inhibitor in preparation of virus reservoir reactivation drugs as well as a composition containing the benzamide histone deacetylase inhibitor. The composition has an obvious effect of activating a reservoir of multiple persistent infection viruses such as human immunodeficiency virus, hepatitis B virus and hepatitis C virus and can be combined with an antiviral agent to obtain a better treatment effect.

Description

technical field [0001] The invention relates to a class of reactivation drugs for the in vivo storage of persistent infection viruses, belonging to the field of microbiology. Background technique [0002] Persistent viral infection refers to the long-term persistent infection state of the body. Since the invading virus cannot kill the host cells, a symbiotic balance is formed between the two. Detoxification, but often lacking clinical symptoms related to immunopathology. Elimination of the latent storage pool formed by latently infected cells is the key to the cure of persistent viral infection diseases. Viruses that cause persistent infections in humans include human immunodeficiency virus (Human Immunodeficiency Virus, HIV), hepatitis B virus (Hepatitis B Virus, HBV), hepatitis C virus (Hepatitis C Virus, HCV) and cytomegalovirus (Cytomegalovirus, CMV )Wait. [0003] HIV [0004] Acquired Immune Deficiency Syndrome (AIDS) is caused by HIV infection and has become a pub...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K45/06A61P31/14A61P31/20A61P31/18A61K31/4406
Inventor 于群任素萍郐启源乔志新王艳冰王璇琳贺敏李伟静王钰
Owner FIELD OPERATION BLOOD TRANSFUSION INST OF PLA SCI ACAD OF MILITARY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com